EyePoint (EYPT) investor relations material

Executive summary

• Report covers the quarter ended June 30, 2026, for a clinical-stage biopharmaceutical company focused on retinal diseases, with DURAVYU as the lead product in Phase 3 trials for wet AMD and DME.

• DURAVYU Phase 3 wet AMD trial enrollment is complete, with topline data from the LUGANO trial expected in August 2026; DME trial enrollment completed in July 2026, with data expected in Q4 2027.

• DURAVYU highlighted as a potential foundational treatment for wet AMD and DME, with multi-mechanism action and strong safety profile.

• Company entered a $4.7 million DOJ settlement and a five-year Corporate Integrity Agreement in July 2026.

• Recent leadership addition: Dr. Tarek S. Hassan appointed Chief Strategic Science Officer in July 2026.

Financial highlights

• Q2 2026 net revenue was $0.5 million, down 90% year-over-year, mainly due to lower license and collaboration revenue and prior deferred revenue recognition.

• Net loss for Q2 2026 was $94.5 million ($1.09 per share), a 59% increase from Q2 2025.

• Operating expenses rose to $97.9 million from $67.6 million year-over-year, driven by Phase 3 trial costs and manufacturing scale-up.

• Research and development expenses rose 51% to $83.6 million in Q2 2026 and 37% to $155.8 million for the six months, driven by DURAVYU Phase 3 trials and manufacturing scale-up.

• Cash, cash equivalents, and marketable securities totaled $180.5 million at June 30, 2026.

Outlook and guidance

• Cash and investments are expected to fund operations into Q4 2027, beyond the anticipated topline data for DURAVYU in wet AMD.

• Company expects continued operating losses and significant R&D spending as clinical programs advance.

• No earnings call scheduled due to imminent LUGANO topline data; update to follow data release.

• DURAVYU positioned as first-to-market sustained release TKI for wet AMD and DME, pending regulatory approval.